AR125085A1 - Profármacos de compuestos de pde10 - Google Patents
Profármacos de compuestos de pde10Info
- Publication number
- AR125085A1 AR125085A1 ARP220100593A ARP220100593A AR125085A1 AR 125085 A1 AR125085 A1 AR 125085A1 AR P220100593 A ARP220100593 A AR P220100593A AR P220100593 A ARP220100593 A AR P220100593A AR 125085 A1 AR125085 A1 AR 125085A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- pde10
- prodrugs
- compounds
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- WQKPZDLZRFTMTI-CABCVRRESA-N 2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=NC(C)=N1 WQKPZDLZRFTMTI-CABCVRRESA-N 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 210000004227 basal ganglia Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a profármacos de 2-metil-N-((5-metil-1,3,4-tiadiazol-2-il)metil)-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciclopropil)metoxi)pirimidin-4-amina que son útiles como agentes terapéuticos para el tratamiento de trastornos del sistema nervioso central asociados a la fosfodiesterasa 10 (PDE10). La presente invención también se refiere al uso de dichos compuestos para el tratamiento de trastornos neurológicos y psiquiátricos, tales como esquizofrenia, psicosis o enfermedad de Huntington, y los asociados a hipofunción del cuerpo estriado o disfunción de los ganglios basales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162333P | 2021-03-17 | 2021-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125085A1 true AR125085A1 (es) | 2023-06-07 |
Family
ID=81325444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100593A AR125085A1 (es) | 2021-03-17 | 2022-03-15 | Profármacos de compuestos de pde10 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11919894B2 (es) |
| EP (1) | EP4308560A1 (es) |
| JP (1) | JP2024509991A (es) |
| KR (1) | KR20230157452A (es) |
| CN (1) | CN117295731A (es) |
| AR (1) | AR125085A1 (es) |
| AU (1) | AU2022238805B2 (es) |
| BR (1) | BR112023018850A2 (es) |
| CA (1) | CA3212082A1 (es) |
| CL (1) | CL2023002724A1 (es) |
| CO (1) | CO2023012333A2 (es) |
| CR (1) | CR20230447A (es) |
| DO (1) | DOP2023000193A (es) |
| EC (1) | ECSP23070522A (es) |
| IL (1) | IL305923A (es) |
| MX (1) | MX2023010824A (es) |
| TW (1) | TWI813203B (es) |
| WO (1) | WO2022197647A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023010824A (es) * | 2021-03-17 | 2023-09-28 | Merck Sharp & Dohme Llc | Profarmacos de compuestos de pde10. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5648147B2 (ja) * | 2011-08-25 | 2015-01-07 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ピリミジンｐｄｅ１０阻害剤 |
| MX2023010824A (es) * | 2021-03-17 | 2023-09-28 | Merck Sharp & Dohme Llc | Profarmacos de compuestos de pde10. |
-
2022
- 2022-03-15 MX MX2023010824A patent/MX2023010824A/es unknown
- 2022-03-15 BR BR112023018850A patent/BR112023018850A2/pt active Search and Examination
- 2022-03-15 WO PCT/US2022/020297 patent/WO2022197647A1/en active Application Filing
- 2022-03-15 IL IL305923A patent/IL305923A/en unknown
- 2022-03-15 JP JP2023556751A patent/JP2024509991A/ja active Pending
- 2022-03-15 US US17/695,125 patent/US11919894B2/en active Active
- 2022-03-15 CR CR20230447A patent/CR20230447A/es unknown
- 2022-03-15 EP EP22715422.6A patent/EP4308560A1/en active Pending
- 2022-03-15 KR KR1020237035230A patent/KR20230157452A/ko active Search and Examination
- 2022-03-15 CN CN202280034653.4A patent/CN117295731A/zh active Pending
- 2022-03-15 AU AU2022238805A patent/AU2022238805B2/en active Active
- 2022-03-15 TW TW111109390A patent/TWI813203B/zh active
- 2022-03-15 CA CA3212082A patent/CA3212082A1/en active Pending
- 2022-03-15 AR ARP220100593A patent/AR125085A1/es unknown
-
2023
- 2023-09-13 CL CL2023002724A patent/CL2023002724A1/es unknown
- 2023-09-14 DO DO2023000193A patent/DOP2023000193A/es unknown
- 2023-09-15 EC ECSENADI202370522A patent/ECSP23070522A/es unknown
- 2023-09-18 CO CONC2023/0012333A patent/CO2023012333A2/es unknown
- 2023-12-13 US US18/538,309 patent/US20240158388A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202300154A (zh) | 2023-01-01 |
| EP4308560A1 (en) | 2024-01-24 |
| IL305923A (en) | 2023-11-01 |
| KR20230157452A (ko) | 2023-11-16 |
| US20220306619A1 (en) | 2022-09-29 |
| TWI813203B (zh) | 2023-08-21 |
| JP2024509991A (ja) | 2024-03-05 |
| ECSP23070522A (es) | 2023-10-31 |
| CN117295731A (zh) | 2023-12-26 |
| AU2022238805A1 (en) | 2023-10-12 |
| BR112023018850A2 (pt) | 2023-10-10 |
| US20240158388A1 (en) | 2024-05-16 |
| CO2023012333A2 (es) | 2023-10-09 |
| US11919894B2 (en) | 2024-03-05 |
| AU2022238805B2 (en) | 2024-05-09 |
| MX2023010824A (es) | 2023-09-28 |
| DOP2023000193A (es) | 2023-11-30 |
| CL2023002724A1 (es) | 2024-05-31 |
| CA3212082A1 (en) | 2022-09-22 |
| WO2022197647A1 (en) | 2022-09-22 |
| CR20230447A (es) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201400014A (es) | Inhibidores de pde10 de pirimidina | |
| CL2011002839A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos positivos de receptores mglur2; composición farmacéutica y su proceso de preparacion; combinación farmaceutica; y su uso en el tratamiento o prevencion de un trastorno del sistema nervioso central tal como ansiedad y esquizofrenia, entre otros. | |
| CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. | |
| CL2011002838A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros. | |
| ECSP19042688A (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| BR112017019685A2 (pt) | composto, composição farmacêutica, uso de um composto ou um sal ou um solvato farmaceuticamente aceitável do mesmo, e, método para tratamento de uma doença ou condição | |
| CO2023012333A2 (es) | Profármacos de compuestos de pde10 | |
| WO2012044561A3 (en) | 2-alkoxy pyrimidine pde10 inhibitors | |
| PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
| CL2007001555A1 (es) | Compuestos derivados de 4-amino-pirido[3,2-e]pirazinas; inhibidores de fosfodiesterasa 10 (pde10); procedimeinto de preparacion; composicion framaceutica; combinacion farmaceutica, y sus uso en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y otros trastornos psicoticos. | |
| WO2012044562A3 (en) | Pyrazolopyrimidine pde10 inhibitors | |
| WO2012054366A3 (en) | Substituted amino-triazolyl pde10 inhibitors | |
| MX2019014597A (es) | Inhibidores de pirazolopirimidina de pde9. | |
| CO2020013462A2 (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
| PE20210948A1 (es) | Moduladores del receptor nmda heteroaromatico y usos de los mismos | |
| PA8781601A1 (es) | " derivados de azaciclilbenzamida como antagonistas de histamina-3 | |
| WO2014150114A8 (en) | Substituted pyridizinone derivatives as pde10 inhibitors | |
| ECSP14013268A (es) | Inhibidores de pde10 de pirimidina | |
| AR112073A1 (es) | Inhibidores de pirazolopirimidina de pde9 | |
| CL2016002066A1 (es) | Derivados de indolarilsulfonamida como antagonistas del receptor 5-ht6 | |
| TH147865A (th) | สารยับยั้ง pde10 ประเภทไพริมิดีน |